GLP1R and diabetes mellitus: Both studies exclude individuals that either are treated with diabetes medication or have been diagnosed with diabetes despite GLP-1 RAs demonstrating their efficacy for reducing obesity-related adverse health effects in adults regardless of obesity status [41].